Building on these pre-clinical studies and to establish the therapeutic efficacy of CDK5 silencing in 3xTg-AD mice, we determined suitable delivery times to obtain reproducible and beneficial effects of shCDK5miR therapy using Adeno-Associated Virus (AAV) vectors. Here, CDK5 is linked to Alzheimer disease.